Evidence map›Paper›PMID 38140102›Full record

ReviewPharmaceutics2023

Advances in Transdermal Drug Delivery Systems: A Bibliometric and Patent Analysis.

Aniello Cammarano, Stefania Dello Iacono, Caterina Meglio, Luigi Nicolais

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Observational
  3. Review
  4. Review
  5. Enhanced Transdermal Delivery of CilnidpinePharmaceutical nanotechnology · 2025
    Article
  6. Article
  7. Observational
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aniello CammaranoMaterias Srl, Corso N. Protopisani 50, 80146 Naples, Italy.ORCID 0000-0001-5188-1272
Stefania Dello IaconoInstitute of Polymers, Composites and Biomaterials (IPCB), National Research Council, P.le Enrico Fermi 1, 80055 Portici, Italy.ORCID 0000-0002-0539-370X
Caterina MeglioMaterias Srl, Corso N. Protopisani 50, 80146 Naples, Italy.
Luigi NicolaisMaterias Srl, Corso N. Protopisani 50, 80146 Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transdermal drug delivery systems have become an intriguing research topic in healthcare technology and one of the most frequently developed pharmaceutical products in the global market. In recent years, researchers and pharmaceutical companies have made significant progress in developing new solutions in the field. This study sheds light on current trends, collaboration patterns, research hotspots, and emerging frontiers of transdermal drug delivery. Herein, a bibliometric and patent analysis of data recovered from Scopus and The Lens databases, respectively, is reported over the last 20 years. From 2000 to 2022, the annual global publications increased from 131 in 2000 to 659 in 2022. Researchers in the United States, China, and India produced the highest number of publications. Likewise, most patent applications have been filed in the USA, China, and Europe. The recovered patents are 7275, grouped into 2997 patent families, of which 314 were granted. This study could support the work of decision-makers, scientific managers, or scientists to create new business opportunities or save money, time, and intellectual capital, thereby defining when a research or technology project should be a priority or not.

Indexed as

bibliometric analysiscontrolled releasepatent analysistransdermal administrationtransdermal drug delivery

Identifiers

PMID38140102
PMCPMC10747220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.